CORONA Remedies: Intimation regarding receipt of GMP Compliance Certification from Brazilian Health Regulatory Agency,…

What happened

CORONA Remedies (CORONA) filed a disclosure with the exchanges on 22 October 2026 at 11:03 AM titled "Intimation regarding receipt of GMP Compliance Certification from Brazilian Health Regulatory Agency, ANVISA, Brazil for OSD manufacturing facility and Hormone manufacturing…".

Company snapshot

CORONA Remedies is a small-cap company in the Healthcare sector, with a market value of about ₹12,456 crore.

The stock last traded at ₹2,036.6, against a 52-week range of ₹1,336.6–₹2,292.4 (11.2% below the high).

Before this filing the shares had moved −8.2% over the month and −1.1% over three months. Average daily turnover over the last 20 sessions was about ₹5.08 crore.

Promoters held 69.00% at the end of Q1 FY27. Foreign institutions owned 3.63% and domestic institutions 12.90%.

What history shows

BCEIE has no earlier approval filing from this company on record since May 2026.

Across 119 similar disclosures by other Healthcare companies, shares moved +0.4% on average the next day and +1.1% over five days; 51% of them rose the next day.

Market-wide, 1,513 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 47% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• 30 October 2026: Board meeting — Financial Results.

In the news

Recent coverage elsewhere (links open the original publisher):

• Corona Remedies Dividend 2026: ₹10.00, Record Date 19 Jun — INDmoney, 16 Oct 2026
• CORONA Remedies Q2 2026 Earnings — https://www.siam.in/, 12 Oct 2026

Source

• Exchange filing (PDF)